Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?

Nature Clinical Practice Cardiovascular Medicine volume 1, pages 18–19 (2004)Cite this article

boxed-textColquhoun D et al. for the LIPID Study Investigators (2004) Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J 25: 771–777

The current evidence best supports the use of statin therapy to reduce LDL by 30% or more as the initial strategy to treat CHD patients with low HDL and normal to low LDL

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Guidelines. Circulation 110: 227–239

    Article  Google Scholar 

  2. Fodor JC et al. (2000) Recommendations for the management and treatment of dyslipidemia: report of the working group on hypercholesterolemia and other dyslipidemias. CMAJ 162: 1441–1447

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Sacks FM and Expert Group on HDL Cholesterol (2002) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90: 139–143

  4. De Backer G et al. (2003) European guidelines on cardiovascular disease prevention: Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24: 1601–1610

    Article  Google Scholar 

  5. Rubins et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Director of the Kim Dayani Center for Health Promotion at Vanderbilt University, Nashville, TN, USA

    David J Maron

Authors
  1. David J Maron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J Maron.

Ethics declarations

Competing interests

DJ Maron has received grant support from Kos Pharmaceuticals Inc., Merck & Co. Inc., Novartis Pharmaceuticals and Pfizer Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maron, D. Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?. Nat Rev Cardiol 1, 18–19 (2004). https://doi.org/10.1038/ncpcardio0006

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0006

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing